← Back to Search

Other

A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants

Phase 1
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new drug, BMS-986419, to see how it affects the body's handling of other common medications in healthy people.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Cocktail Probe Substrates + BMS-986419Experimental Treatment7 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Caffeine
2014
Completed Phase 3
~2980
Bupropion
2011
Completed Phase 4
~3310
Midazolam
2018
Completed Phase 4
~1910
Flurbiprofen
2022
Completed Phase 4
~870
BMS-986419
2023
Completed Phase 1
~30
Omeprazole
2006
Completed Phase 4
~940
Fexofenadine
2016
Completed Phase 4
~950

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,691 Previous Clinical Trials
4,097,566 Total Patients Enrolled

Media Library

BMS-986419 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05932277 — Phase 1
Healthy Subjects Research Study Groups: Cocktail Probe Substrates + BMS-986419
Healthy Subjects Clinical Trial 2023: BMS-986419 Highlights & Side Effects. Trial Name: NCT05932277 — Phase 1
BMS-986419 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05932277 — Phase 1
~9 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top